REMEDOR BIOMED PL sp z o.o.
European center for the development of biological drugs
Advancing innovative biologic therapies from scientific discovery to clinical application
The Diabetic Foot Problem
Remedor Poland is the European center of research and development within the Remedor Group and the prospective EU operations base. We develop innovative biological therapies for diseases that represent a serious challenge for modern medicine and currently we focus on diabetic foot ulcers.
Our operations cover all development stages ranging from early stage technology and formulation development up to pre-clinical validation and preparation for clinical trials, as well as further manufacturing and wholesale.
Together with the best Polish medical universities, clinicians and international specialists, we bring scientific innovations to safe and efficient therapeutics.
Why Poland?
Building innovation in one of Europe's fastest-growing life science ecosystems
Poland provides a distinctive platform for advanced medicinal products development.
Remedor Poland benefits from:
• collaboration with internationally recognized medical universities,
• involvement of professional clinical investigators and top class scientific professionals,
• rapid development of the biotech infrastructure,
• active innovation and technology transfer promotion,
• direct access to the European pharmaceutical market.
It helps to develop innovative products efficiently, complying with strict scientific and regulatory standards.
Our Flagship Programme
"EpoDerm" a novel biologic therapy for diabetic foot ulcers
Diabetic foot ulcers continue to be one of the most dangerous complications of diabetes, as millions of patients all around the world suffer from them, which often results in infections, hospitalisation and limb amputation.
EpoDerm is an innovative biologic drug, which is developed in order to deliver recombinant human erythropoietin to the chronic wound in a sustainable way by means of a special hydrogel system.
This project integrates pharmaceutical science, biomaterials, molecular biology and clinical medicine for developing a drug, which can enhance the wound healing process without any adverse systemic effects.